TransCode Therapeutics received letters from Nasdaq indicating it does not meet the minimum bid price and stockholders equity requirements for continued listing, with stockholders equity reported at $1,322,274, below the required $2,500,000, and an appeal is pending for a hearing on October 1, 2024.